Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion (Nasdaq: ACON) said Texas Spine Care Center will join its 300-patient, prospective randomized CLARITY trial evaluating Nociscan for surgical treatment of discogenic chronic low back pain. The primary endpoint is 12-month change in VAS back pain. Aclarion expects an initial internal readout and early interim results disclosure in Q4 2026.
How this was made
The 30-second read
Why it matters
The new Texas Spine Care Center site expands the CLARITY network, which can help recruitment and operational execution, but the article does not provide new clinical results or updated financial expectations.
Market read
This is a trial-enrollment execution update for ACON with a stated expectation of early interim results in Q4 2026, but no new efficacy/safety datapoint.
What to watch
Key risk remains whether Nociscan’s trial endpoints (VAS change at 12 months) will be met; this release doesn’t address recruitment status, adherence, or interim data quality.
Background
Aclarion’s CLARITY is a 300-patient randomized multi-center trial evaluating Nociscan for discogenic chronic low back pain surgery outcomes.
Ticker impact
Aclarion added Texas Spine Care Center as a new CLARITY trial site for Nociscan, expanding enrollment ahead of Q4 2026 interim results.
Likely limited near-term impact; any move would be tied to broader clinical-trial sentiment rather than new results.
The release is a prospective trial logistics update (new site, 300-patient design) with an expected internal readout and early interim disclosure in Q4 2026, but it provides no new endpoint data or guidance changes.
Market effects
Supports sentiment for precision diagnostics/biomarker-driven spine care platforms, but does not change competitive benchmarks in this text.
Primarily US clinical-trial execution; no specific regional reimbursement or policy change mentioned.
Chronic low back pain is framed globally, but the disclosed update is a US site addition only.
Counterpoint
Adding a site may not materially de-risk timelines if patient recruitment pace or site performance varies; without enrollment numbers, impact is uncertain.
Key entities
- companyAclarion, Inc.
Healthcare technology company developing Nociscan for identifying painful lumbar discs using MR spectroscopy and AI.
- clinical_trialCLARITY trial
300-patient prospective randomized multi-center study evaluating Nociscan in surgical patients; primary endpoint is VAS back pain change at 12 months.
- clinical_siteTexas Spine Care Center
San Antonio orthopedic spine practice added as a new CLARITY site.
- productNociscan
SaaS platform using MR spectroscopy biomarkers and augmented intelligence to distinguish painful vs nonpainful lumbar discs.
